E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Systemic Lupus Erythematosus |
Lupus Eritematoso Sistémico |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10042945 |
E.1.2 | Term | Systemic lupus erythematosus |
E.1.2 | System Organ Class | 10028395 - Musculoskeletal and connective tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of ustekinumab as measured by a reduction in disease activity for subjects with active SLE |
El objetivo principal consiste en evaluar la eficacia de ustekinumab en función de la disminución de la actividad de la enfermedad en pacientes con LES activo. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate: ? The safety and tolerability of ustekinumab in subjects with SLE. ? The effect of ustekinumab administration on health-related quality of life in subjects with SLE. ? The effects of ustekinumab on cutaneous manifestations of SLE. ? Pharmacokinetics and immunogenicity of ustekinumab in subjects with SLE |
Los objetivos secundarios consisten en evaluar: ? La seguridad y tolerabilidad de ustekinumab en pacientes con LES. ? El efecto de la administración de ustekinumab en la calidad de vida relacionada con la salud en pacientes con LES. ? Los efectos de ustekinumab en las manifestaciones cutáneas del LES. ? La farmacocinética y la inmunogenicidad de ustekinumab en pacientes con LES. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Protocol A0 - dated 18 December 2014 - Subjects who provide consent will be enrolled in the cutaneous lupus substudy evaluating the histology of cutaneous biopsies and/or skin photographs. Subjects participating in the cutaneous lupus substudy are not required to undergo biopsies, and may allow only photographs to document changes in an identified lesion or area of active disease |
Protocolo AO - del 18 de diciembre de 2014 - Los pacientes que otorguen su consentimiento serán reclutados en el subestudio del lupus cutáneo para evaluar la histología de las biopsias cutáneas y/o las fotografías de la piel. Los pacientes que participen en el subestudio del lupus cutáneo no tendrán por qué realizarse biopsias y podrán otorgar su consentimiento únicamente para la obtención de fotografías que documenten cambios en una lesión identificada o una zona de enfermedad activa. |
|
E.3 | Principal inclusion criteria |
- Subjects must have documented medical history to meet SLICC classification criteria for SLE for a minimum of 3 months prior to first dose - At least 1 well-documented (subject file, referring physician letter, or laboratory result), unequivocally positive, test for autoantibodies in medical history including either of the following: ANA, and/or anti-dsDNA antibodies, and/or anti-Smith antibodies - At least 1 unequivocally positive autoantibody test including ANA and/or anti-dsDNA antibodies and/or anti-Smith antibodies detected during screening - At least 1 BILAG A and/or 2 BILAG B domain scores observed at screening and/or at Week 0 prior to first administration of study agent - Demonstrate active disease based on SLEDAI-2K score greater than or equal to (>=) 6 observed during screening and assessed approximately 2 to 6 weeks prior to randomization (Week 0). - Must also have SLEDAI-2K score >= 4 for clinical features (ie, SLEDAI excluding laboratory-based items) at Week 0 prior to the first administration of study agent |
- Los pacientes deben tener antecedentes médicos documentados que cumplan los criterios de clasificación de SLICC para el LES desde por lo menos 3 meses antes de recibir la primera dosis - Al menos un análisis debidamente documentado (archivo del paciente, carta del médico que le ha derivado o resultado analítico) e inequívocamente positivo de autoanticuerpos en la historia clínica, incluido cualquiera de los siguientes: AAN, anticuerpos anti-ADNbc o anticuerpos anti-Smith -Al menos un resultado positivo en un análisis de autoanticuerpos (anticuerpos antinucleares [AAN], anticuerpos contra el ácido desoxirribonucléico bicatenario (anti-ADNbc) o anticuerpos anti-Smith) durante la selección - Al menos una puntuación BILAG A en un dominio y/o una puntuación BILAG B en dos dominios en la selección y/o en la semana 0 antes de la administración de la primera dosis del fármaco del estudio. - Presentar enfermedad activa basada en una puntuación de SLEDAI-2K ?6 observada durante la selección y evaluada aproximadamente entre 2 y 6 semanas antes de la aleatorización (semana 0). - Obtener también una puntuación SLEDAI-2K ?4 para las manifestaciones clínicas (es decir, SLEDAI excluidos los criterios analíticos) en la semana 0 antes de la administración de la primera dosis del fármaco del estudio. |
|
E.4 | Principal exclusion criteria |
- Have other inflammatory diseases that might confound the evaluations of efficacy, including but not limited to rheumatoid arthritis (RA), psoriatic arthritis (PsA), RA/lupus overlap, psoriasis or Lyme disease - Are pregnant, nursing, or planning a pregnancy or fathering a child while enrolled in the study or within 4 months after receiving the last administration of study agent - Have received systemic immunosuppressives other than those described in inclusion criteria within the past 6 months prior to first administration of study agent - Have received more than 1 previous B cell targeting therapy including belimumab or epratuzamab within 6 months prior to first administration of the study agent or received B-cell depleting therapy (eg, rituximab) within 12 months prior to first administration of the study agent or have evidence of continued B-cell depletion following such therapy - Have ever received ustekinumab |
- Presentar enfermedades inflamatorias que puedan confundir las evaluaciones de la eficacia, como artritis reumatoide (AR), artritris psoriásica (APs), solapamiento de AR/lupus, psoriasis o enfermedad de Lyme. - Embarazo, lactancia o intención de quedarse embarazada o engendrar un hijo durante la participación en el estudio o en las 4 meses siguientes a la administración de la última dosis del fármaco del estudio. - Haber recibido tratamiento sistémico con inmunodepresores distintos a los descritos en los criterios de inclusión en los 6 meses previos a la administración de la primera dosis del fármaco del estudio. -Haber recibido más de un tratamiento previo dirigido a los linfocitos B, como belimumab o epratuzumab en los 6 meses previos a la administración de la primera dosis del fármaco del estudio, o haber recibido un tratamiento reductor de linfocitos B (p. ej., rituximab) en los 12 meses previos a la administración de la primera dosis del fármaco del estudio o presentar signos de reducción persistente de linfocitos B después de dicho tratamiento. -Haber recibido alguna vez antes ustekinumab. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Percentage of Participants With a Composite SRI-4 Response at Week 24 |
La proporción de pacientes con una respuesta SRI-4 compuesta en la semana 24. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- Change From Baseline in SLEDAI-2K Score at Week 24. - Change From Baseline in Physician Global Assessment of Disease Activity (PGA) at Week 24 - Percentage of Participants With BICLA Response at Week 24 |
- Variación respecto al valor basal de SLEDAI-2K en la semana 24. - Variación respecto al momento basal de la EGM en la semana 24. - Proporción de pacientes con respuesta BICLA en la semana 24. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 18 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Australia |
Germany |
Hungary |
Mexico |
Poland |
Spain |
Taiwan |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LSLV |
Última visita del último paciente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 13 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 13 |